Jenna Ventorino

Jenna is a corporate attorney who provides strategic counsel to public and private life sciences companies across all stages of growth. Drawing on her experience as in-house counsel and her scientific background, she helps clients navigate complex legal and business challenges with a practical, solutions-oriented approach.

Jenna’s practice focuses on life sciences partnering transactions, including inbound and outbound licensing, technology acquisitions and divestitures, joint ventures, strategic alliances and R&D collaborations. Her clients include companies developing cutting-edge solutions, such as gene-editing technologies, antibody therapeutics and next-generation biotech platforms. She regularly advises companies throughout their corporate life cycle on a range of intellectual property-related issues, from foundational institutional licenses to later-stage commercial partnerships and IP-focused M&A transactions.

In addition to her transactional work, Jenna is deeply engaged in the legal and business community. She serves as a director of the Women’s Bar Association, sits on the Greater Boston Chamber of Commerce Women’s Network Advisory Board and mentors law students through the Boston University School of Law. Her commitment to supporting women-led ventures is reflected in her leadership of initiatives that elevate women founders and innovators in the life sciences sector.

Representative matters

• Counseled a global healthcare company in its strategic collaboration to create a portfolio of transformational medicines*
• Advised an antibody services and technology provider in library development agreements with various partners and in its acquisition by a global provider of life sciences service solutions*
• Represented the developer of a machine-learning drug discovery platform in its acquisition by a precision medicine company*
• Represented a biopharmaceutical company in the in-license of various checkpoint inhibitors from a Chinese biopharmaceutical company*
• Counseled a public, clinical-stage genome-editing company in the buildout and execution of its out- licensing strategy, as well as in various strategic collaboration agreements with global pharmaceutical companies*
• Represented a biotechnology company in its license and supply agreements with a global pharmaceutical company to commercialize its first-to-market gene therapy product outside of the US*
• Counseled a gene therapy company in multiple development-stage collaboration agreements with various strategic partners*
• Advised a venture-backed life sciences incubator in its strategic drug discovery collaborations with several major research institutions*
• Advised a national research university in out-licensing and sponsored research transactions*
• Counseled a pharmaceutical company focused on treatments for iron deficiency anemia in adult patients in connection with a license and commercialization agreement*
• Represented a privately held biopharmaceutical company in the sale of its lead preclinical pain program to a research-based pharmaceutical and biotechnology company*

* Representation handled before joining Cooley